DPP4 and metabolic dysfunction-associated steatohepatitis: Indeed, in murine models of NASH and fibrosis, the dipeptidyl-peptidase-4 (DPP4) inhibitors (gliptins) significantly decreased parameters of steatosis and inflammation, which was accompanied by a suppression of hepatic transcript levels reflecting inflammation (IL-1β, TNFα and MCP-1) and fibrosis (asserted by α-SMA immunostaining).